A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs FE 201836 (Primary) ; Desmopressin
- Indications Nocturia
- Focus Therapeutic Use
- Acronyms DAWN
- Sponsors Ferring Pharmaceuticals
- 21 Sep 2018 Planned End Date changed from 25 Jul 2020 to 22 Nov 2019.
- 21 Sep 2018 Planned primary completion date changed from 25 Jul 2020 to 22 Nov 2019.
- 17 Aug 2018 Planned End Date changed from 25 Oct 2019 to 25 Jul 2020.